Overall, 44 (9.3%) received ROP treatment, including 28 infants who underwent laser therapy and 16 infants who were given an anti-VEGF drug (Ranibizumab) via intraocular injections (Figure 1). This evidence concerns the gene VEGFA and retinopathy of prematurity.